Dr. Raghu Kalluri speaks with Cancer Network about the role of exosomes in cancer progression ahead of his presentation at ESMO 2018.
In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
Dr. William Pirl speaks with Cancer Network about cancer patients' moods influencing their well-being and survival.
Five notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).
In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
This article discusses some of the popular diets that cancer patients pursue, and the positive and negative aspects associated with these diets.
This article discusses ways in which the oncologist can incorporate value into the management of patients with lung cancer and comply with the underlying principles of the Choose Wisely Campaign, as well as recent ASCO and ESMO initiatives, to bend the cost curve downwards while maintaining efficacy.
This article discusses ways in which the oncologist can incorporate value into the management of patients with lung cancer and comply with the underlying principles of the Choose Wisely Campaign, as well as recent ASCO and ESMO initiatives, to bend the cost curve downwards while maintaining efficacy.
In this article, we review the role of temozolomide in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers.
Dr. Denise Faustman spoke with Cancer Network about TNFR2 and its emerging role in understanding regulatory T-cell behavior.
Dr. William Newman spoke with Cancer Network about the roles of epigenetic silencing in heritable cancer syndromes.
An expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.
Dr. Filip Janku speaks with Cancer Network about a phase I clinical trial investigating the use of bacterial clostridium novyi-NT in solid tumors.
Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.
The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.
Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
In this article, Dr. Mona Patel discusses how to best manage dyspnea in cancer patients, with both pharmacologic and nonpharmacologic approaches.
In this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
In this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.